Jérémie Pariente

Also affiliated with Inserm, Université Fédérale de Toulouse Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Hôpital Paule de Viguier, Toulouse NeuroImaging Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial”.

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

The Lancet Neurology(2025)10.1016/s1474-4422(25)00024-9

N/A

1.2DataRank · unranked

41 citations

Yan Li, Eric McDade, Jorge J. Llibre‐Guerra, David B. Clifford, Alireza Atri +62 more

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease

JAMA Neurology(2024)10.1001/jamaneurol.2024.0991

N/A

1.0DataRank · unranked

29 citations

Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner, Marzia A. Scelsi +94 more

Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease

European Journal of Nuclear Medicine and Molecular Imaging(2023)10.1007/s00259-023-06209-0

N/A

0.765DataRank · unranked

24 citations

Austin McCullough, Brian A. Gordon, Nelly Joseph‐Mathurin, Shaney Flores, Nicole S. McKay +48 more

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial

medRxiv(2024)10.1101/2024.10.29.24316289

N/A

0.351DataRank · unranked

6 citations

Yan Li, Eric McDade, Jorge J. Llibre‐Guerra, David B. Clifford, Alireza Atri +63 more

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Nature Medicine(2021)10.1038/s41591-021-01369-8

N/A

0DataRank · unranked

365 citations

Martin R. Farlow, Eric McDade, David B. Clifford, Guoqiao Wang, Jorge J. Llibre‐Guerra +61 more

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials

The Journal of Prevention of Alzheimer s Disease(2024)10.14283/jpad.2024.61

N/A

0DataRank · unranked

4 citations

Jonathan Li, Ellen Ziegemeier, Sarah F. Adams, Eric McDade, David B. Clifford +34 more